Lung Cancer: Importance of Multidisciplinary Collaboration
Expert Perspectives
Expert Perspectives

Lung Cancer: Importance of Multidisciplinary Collaboration

Not a member of My prIME? Join now for instant access.

Expand your knowledge of lung cancer with this discussion featuring Frank Detterbeck, MD; Erik Folch, MD; and Raymond Osarogiagbon, MD. This expert faculty explores the importance of multidisciplinary collaboration and practical considerations for patient management.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.75 AMA PRA Category 1 Credits™

CE

CE

1.75 Contact Hours

Release Date

Release Date

Nov 21, 2017

Expiration Date

Nov 21, 2018

Moderator

  • Raymond Osarogiagbon, MDBaptist Memorial Hospital-Memphis
    Memphis, Tennessee, United States

Faculty

  • Frank C. Detterbeck, MD, FACS, FCCPYale Cancer Center
    New Haven, Connecticut, United States
  • Erik E. Folch, MD, MScMassachusetts General Hospital
    Boston, Massachusetts, United States
  • Multidisciplinary management of NSCLC
  • Case discussions
  • Shared decision making

This activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, nurses, pulmonologists, pathologists, and other healthcare professionals involved in the treatment of patients with lung cancer.

After successful completion of this educational activity, participants should be able to:

  • Assess treatment options for first and subsequent lines of therapy for NSCLC
  • Explain the importance of multidisciplinary collaboration in the management of NSCLC
  • Describe how multidisciplinary management can improve outcomes for patients with NSCLC

This activity was developed in collaboration with the Addario Lung Cancer Foundation.

This educational activity is supported by grants from Bristol-Myers Squibb; Celgene Corporation; Lilly USA, LLC; and Merck and Co, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Lung Cancer: Importance of Multidisciplinary Collaboration - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This continuing nursing education activity was approved by the ONS, an accredited approver by the American Nurses Credentialing Center’s COA.

A maximum of 1.75 contact hours may be earned for successful completion of this program. The criteria for successful completion include attending the full program and completing the evaluation.

Content in this learning activity is applicable to meeting individual requirements for certification renewal through the Oncology Nursing Certification Corporation’s Independent Learning Needs Assessment (ILNA) renewal method. Visit www.oncc.org for complete details on oncology nursing certification.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

A link to the posttest is available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Detterbeck has disclosed that he has received support for travel to meetings from Medela. He has also received fees for participation in advisory or review activities from Spiration, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

Dr Folch has disclosed that he has received research funding from Medtronic. He has also received fees for participation in advisory or review activities from Boston Scientific. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

Dr Osarogiagbon has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Brooke Balun, MSN, APRN-BC, AOCNP (lead nurse planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.